MicroRNAs and Alarmins in Cardio-Oncology: Biomarkers and Therapeutic Implications in Skin and Breast Cancer
Authors:
- Federica CannistràFCFederica Cannistrà
- Sara SilenoSSSara Sileno
- Francesco CribariFCFrancesco Cribari
- Marco D’AgostinoMDMarco D’Agostino
- Francesco MartinoFMFrancesco Martino
- Francesco MorroneFMFrancesco Morrone
- Guido MelilloGMGuido Melillo
- Federica LimanaFLFederica Limana
- Alessandra MagentaAMAlessandra Magenta
Open Access
- 19 September 2026
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8329
Abstract
Cardio-oncology explores the complex interplay between cancer biology and cardiovascular health, particularly the cardiotoxic effects of cancer therapies. Both microRNAs (miRNAs) and alarmins have emerged as key molecular mediators linking tumor progression and cardiac stress, representing promising biomarkers and therapeutic targets. In skin and breast cancer, specific miRNAs, including miR-21, miR-155, miR-34a, and the miR-200 family, regulate tumor proliferation, invasion, metastasis, and therapy resistance. Alarmins such as NPM, HMGB1, HSPs, IL-33, and S100 proteins modulate inflammatory signaling, oxidative stress, and tissue remodeling, contributing to both tumor progression and cardiomyocyte dysfunction. These molecules are also implicated in chemotherapy- and targeted therapy-induced cardiotoxicity, including apoptosis, fibrosis, and impaired cardiac function. This review highlights the dual role of miRNAs and alarmins in tumor biology and cardiovascular toxicity, emphasizing their potential as circulating biomarkers for early detection and monitoring. Therapeutic strategies targeting this axis—including miRNA mimics/inhibitors and alarmin modulators—may provide synergistic benefits by reducing cardiotoxicity while suppressing tumor growth. Understanding miRNA–alarmin relationships, including direct interactions such as the NPM/miR-200c axis, as well as their broader regulatory networks in cardio-oncology, offers novel avenues for precision medicine, enabling integrated approaches to monitor, prevent, and treat therapy-related cardiac complications in patients with skin and breast cancers.Keywords
Funding Information
- Ministry of Health, Uganda (RC 2025)
This publication has 298 references indexed in Scilit:
- Prevention of Cancer Therapy-Related Cardiac Dysfunction and Heart Failure in Cancer Patients and Survivors. A Clinical Consensus Statement of the Heart Failure Association, the European Association of Preventive Cardiology of the ESC, and the ESC Council of Cardio-OncologyEuropean Journal of Heart Failure, 2025
- Immune Checkpoint Inhibitor–Induced CardiotoxicityJAMA Oncology, 2024
- Incidence, risk factors, and management of alpelisib‐associated hyperglycemia in metastatic breast cancerCancer, 2023
- Targeting immunogenic cell death in cancerMolecular Oncology, 2020
- miR‐140‐5p is negatively correlated with proliferation, invasion, and tumorigenesis in malignant melanoma by targeting SOX4 via the Wnt/β‐catenin and NF‐κB cascadesJournal of Cellular Physiology, 2019
- Cardiovascular Adverse Events Associated With BRAF and MEK InhibitorsJAMA Network Open, 2019
- Epigenetic silencing of miR‐200c in breast cancer is associated with aggressiveness and is modulated by ZEB1Genes, Chromosomes and Cancer, 2016
- Circulating mir-208a fails as a biomarker of doxorubicin-induced cardiotoxicity in breast cancer patientsJournal of Applied Toxicology, 2015
- Plasma miR‐208 as a useful biomarker for drug‐induced cardiotoxicity in ratsJournal of Applied Toxicology, 2014
- Interleukin‐33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cellsInternational Journal of Cancer, 2013